For a 52‑year‑old patient with a BMI of 30.4, how can I obtain insurance approval for semaglutide (Wegovy) and which ICD‑10‑CM codes should be used?

Insurance Approval Strategy for Wegovy (Semaglutide 2.4 mg)

For your 52-year-old patient with BMI 30.4, use ICD-10 code E66.9 (Obesity, unspecified) as the primary diagnosis, and document any weight-related comorbidities with their specific codes to strengthen the prior authorization.

Required ICD-10 Codes

Primary Diagnosis

• E66.9 - Obesity, unspecified (BMI 30.4 qualifies)

Document Weight-Related Comorbidities (if present)

Adding these significantly improves approval rates 1, 2:

• E11.9 - Type 2 diabetes mellitus (if present)
• I10 - Essential hypertension
• E78.5 - Hyperlipidemia, unspecified
• G47.33 - Obstructive sleep apnea
• K76.0 - Fatty liver disease (NAFLD/NASH)
• M17.9 - Osteoarthritis of knee
• Z68.30-Z68.39 - BMI codes (Z68.30 for BMI 30.0-30.9)

FDA-Approved Indications

Wegovy is FDA-approved for chronic weight management in adults with 3:

• BMI ≥30 kg/m² (your patient qualifies), OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)

Your patient meets criteria with BMI 30.4 alone, but documenting comorbidities strengthens the case.

Prior Authorization Strategy

1. Document Failed Lifestyle Modification

Insurance requires evidence of inadequate response to lifestyle interventions 2, 4:

• Document 3-6 months of supervised diet and exercise attempts
• Include weight logs showing <5% weight loss
• Note dietitian visits or structured weight loss program participation

2. Emphasize Clinical Benefits Beyond Weight

Semaglutide 2.4 mg has FDA approval for cardiovascular risk reduction in patients with obesity and established cardiovascular disease 5, 6. If applicable, document:

• Cardiovascular disease history
• Cardiovascular risk factors
• This March 2024 expanded indication significantly improved Medicare Part D coverage 6

3. Letter of Medical Necessity Components

Include these elements:

Patient-specific justification:

• BMI 30.4 meets FDA criteria
• List all weight-related comorbidities with ICD-10 codes
• Document failed lifestyle interventions (dates, duration, results)
• Note contraindications to alternative medications if applicable

Clinical evidence:

• Reference STEP trials showing 14.9-16.9% weight loss at 68 weeks 4, 5
• Cite cardiovascular benefits if patient has CVD 5
• Note superior efficacy compared to other anti-obesity medications 2, 4

Treatment plan:

• Specify titration schedule: 0.25 mg weekly × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg × 4 weeks → 1.7 mg × 4 weeks → 2.4 mg maintenance 2
• Commit to monitoring response at 3-4 months (discontinue if <5% weight loss) 7

Common Insurance Barriers and Solutions

Cost/Coverage Issues

• Medicare Part D: Now covers Wegovy for cardiovascular risk reduction (March 2024 expansion) 6. Code cardiovascular disease prominently.
• Commercial insurance: Approval rates vary by plan type; point-of-service plans show higher approval rates 8
• High copayments: Associated with 51% discontinuation rates in highest quintile 9. Consider manufacturer savings programs or patient assistance

Step Therapy Requirements

Some insurers require trials of:

• Phentermine/topiramate ER
• Naltrexone/bupropion ER
• Liraglutide 3.0 mg
• Orlistat

Document contraindications or failures of these alternatives if required 2.

Appeal Strategy if Denied

1. Peer-to-peer review: Request physician-to-physician discussion
2. Cite guideline recommendations: AGA, AACE, and AASLD guidelines recommend semaglutide 2.4 mg as preferred agent 1, 2, 5
3. Emphasize superior efficacy: Semaglutide shows greatest weight loss (10.3-12.4% placebo-subtracted) versus other approved medications 2, 4
4. Reference cardiovascular benefits: SELECT trial showed 20% reduction in MACE 5

Critical Documentation Points

In your medical record, explicitly state:

• "Patient meets FDA criteria for Wegovy with BMI 30.4"
• "Failed to achieve ≥5% weight loss despite 6 months of lifestyle modification including [specific interventions]"
• "Patient has the following weight-related comorbidities: [list with ICD-10 codes]"
• "Alternative anti-obesity medications are contraindicated/failed due to [specific reasons]"
• "Treatment goal: ≥10% weight loss to reduce cardiovascular and metabolic risk"

Monitoring Requirements for Continued Coverage

Document at 3-4 month follow-up 7, 2:

• Weight loss ≥4-5% to justify continuation
• Tolerability assessment
• Comorbidity improvement (blood pressure, glucose, lipids)
• Plan for long-term therapy (weight regain occurs with discontinuation) 4

Common pitfall: Insurers may deny if early weight loss targets aren't met. The FDA label and guidelines specify discontinuation if <5% weight loss after 12 weeks at maintenance dose 7. Document response early and clearly.